Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 6, 2007, Pages 580-587

  Scott, Charles ^a   Suh, John ^b   Stea, Baldassarre ^c   Nabid, Abdenour ^d   Hackman, John ^e  

^a CBS   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^e Allos Therapeutics Inc   (United States)

Author keywords

Brain metastases; Breast cancer; Efaproxiral; Quality of life; Whole brain radiation therapy

Indexed keywords

CORTICOSTEROID; EFAPROXIRAL; EFAPROXYN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; QUALITY OF LIFE; QUALITY OF LIFE INDEX; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANILINE COMPOUNDS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CRANIAL IRRADIATION; FEMALE; HUMANS; MIDDLE AGED; OXYGEN; PROPIONIC ACIDS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RADIATION DOSAGE; RADIATION-SENSITIZING AGENTS; SURVIVAL RATE;

EID: 37349077910     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3180653c0d     Document Type: Article

References (42)

1. Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol. 2006;24:106-114.
2. Hall EJ. The oxygen effect and reoxygenation. In: Hall EJ, ed. Radiobiology for the Radiologist. Philadelphia: Lippincott; 1988:137-160.
3. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285-289.
4. De Santis M, Balducci M, Basilico L, et al. Radiotherapy, local control and survival in brain tumors. Rays. 1998;23:543-548.
5. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys. 1994;29:427-431.
6. 2 tension measurements. Cancer Res. 1991;51:3316-3322.
7. 2 tension measurements. Cancer Res. 1991;51:6098-6102.
8. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988;14:831-838.
9. Posner JB. Management of brain metastases. Rev Neurol. 1992;148:477-487.
10. Wen PY, Loeffler JS. Management of brain metastases. Oncology (Huntingt). 1999;13:941-954; discussion 961.
11. Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer. 1981;48:384-394.
12. Lee Y-T. Breast carcinoma: pattern of metastases at autopsy. J Surg Oncol. 1983;23:175-180.
13. Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastasis from breast carcinoma: autopsy study. Cancer. 1983;52:2349-2354.
14. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972-2977.
15. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608-3617.
16. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-751.
17. DiBiase SJ, Chin LS, Ma L. Influence of gamma knife radiosurgery on the quality of life in patients with brain metastases. Am J Clin Oncol. 2002;25:131-134.
18. Moinpour CM, Lyons B, Schmidt SP, et al. Substituting proxy ratings for patient ratings in cancer clinical trials: an analysis based on a southwest oncology group trial in patients with brain metastases. Qual Life Res. 2000;9:219-231.
19. Chow E, Davis L, Holden L, et al. Prospective assessment of patient-rated symptoms following whole brain radiotherapy for brain metastases. J Pain Symptom Manage. 2005;30:18-23.
20. Bezjak A, Adam J, Barton R, et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer. 2002;38:487-496.
21. Sehlen S, Lenk M, Hollenhorst H, et al. Quality of life (QOL) as predictive mediator variable for survival in patients with intracerebral neoplasm during radiotherapy. Onkologie. 2003;26:38-43.
22. Tsao MN, Mehta MP, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys. 2005;63:47-55.
23. Mehta MP, Tsao MN, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2005;63:37-46.
24. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 1980;6:1-9.
25. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
26. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 1981;34:585-597.
27. Ventafridda V, De Conno F, Vigano A, et al. Comparison of home and hospital care of advanced cancer patients. Tumori. 1989;75:619-625.
28. Greimel E, Thiel I, Peintinger F, et al. Prospective assessment of quality of life of female cancer patients. Gynecol Oncol. 2002;85:140-147.
29. Loberiza FR Jr, Rizzo JD, Bredeson CN, et al. Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol. 2002;20:2118-2126.
30. Paccagnella A, Favaretto A, Oniga F, et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer: a multicenter, randomized phase III trial. Lung Cancer. 2004;43:83-91.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
32. Peto R, Peto J. Asymptotically efficient rank invariant test procedures [with discussion]. J Royal Stat Soc A. 1962;135:185-206.
33. Wyrwich KW, Wolinsky FD. Identifying meaningful intra-individual change standards for health-related quality of life measures. J Eval Clin Pract. 2000;6:39-49.
34. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52:861-873.
35. Wyrwich KW, Nienaber NA, Tierney WM, et al. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care. 1999;37:469-478.
36. Eton DT, Cella D, Yost KJ, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004;57:898-910.
37. Potthoff RF, Tudor GE, Pieper KS, et al. Can one assess whether missing data are missing at random in medical studies? Stat Methods Med Res. 2006;15:213-234.
38. Park T, Lee SY. A test of missing completely at random for longitudinal data with missing observations. Stat Med. 1997;16:1859-1871.
39. Gelber RD, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol. 1986;4:1772-1779.
40. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med. 1990;9:1259-1276.
41. Hwang JS, Tsauo JY, Wang JD. Estimation of expected quality adjusted survival by cross-sectional survey. Stat Med. 1996;15:93-102.
42. Willan AR, Chen EB, Cook RJ, et al. Incremental net benefit in randomized clinical trials with quality-adjusted survival. Stat Med. 2003;22:353-362.